Bcl-xL Genetic Modification Enhanced the Therapeutic Efficacy of Mesenchymal Stem Cell Transplantation in the Treatment of Heart Infarction

Figure 2

The surface marker expression of genetically modified rat MSCs. The expressions of selected surface markers of the modified MSCs were analyzed by flow cytometry. Mouse IgG1 was used as an isotype control (a); in the genetically modified MSCs, CD29, CD90, and CD44 were highly expressed ((b)–(d)) while the markers for hematopoietic stem cells, CD34 and CD45, were not expressed ((e) and (f)).

(a)

(b)

(c)

(d)

(e)

(f)